S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of (Ad)
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
Sell every Stock except ONE (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of (Ad)
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
Sell every Stock except ONE (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of (Ad)
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
Sell every Stock except ONE (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of (Ad)
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
Sell every Stock except ONE (Ad)
NASDAQ:CHRS

Coherus BioSciences - CHRS Stock Forecast, Price & News

$13.76
+1.11 (+8.77%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$12.64
$13.93
50-Day Range
$5.86
$13.76
52-Week Range
$5.60
$19.32
Volume
1.24 million shs
Average Volume
1.21 million shs
Market Capitalization
$1.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.40

Coherus BioSciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
33.7% Upside
$18.40 Price Target
Short Interest
Bearish
14.64% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.53
Upright™ Environmental Score
News Sentiment
0.80mentions of Coherus BioSciences in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.42) to ($0.93) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

493rd out of 1,135 stocks

Biological Products, Except Diagnostic Industry

71st out of 180 stocks

CHRS stock logo

About Coherus BioSciences (NASDAQ:CHRS) Stock

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Coherus BioSciences Price Performance

NASDAQ:CHRS traded up $1.11 on Friday, reaching $13.76. The company's stock had a trading volume of 1,238,439 shares, compared to its average volume of 1,210,397. Coherus BioSciences has a twelve month low of $5.60 and a twelve month high of $19.32. The company has a debt-to-equity ratio of 33.47, a current ratio of 3.17 and a quick ratio of 2.95. The firm's 50 day moving average is $8.31 and its two-hundred day moving average is $9.97.

Coherus BioSciences (NASDAQ:CHRS - Get Rating) last released its earnings results on Thursday, August 4th. The biotechnology company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.64) by $0.17. Coherus BioSciences had a negative net margin of 83.47% and a negative return on equity of 422.10%. During the same period in the prior year, the company posted ($0.40) EPS. As a group, equities research analysts forecast that Coherus BioSciences will post -3.42 EPS for the current fiscal year.

Analysts Set New Price Targets

CHRS has been the topic of several recent analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Coherus BioSciences in a research note on Tuesday, May 3rd. Mizuho decreased their target price on shares of Coherus BioSciences from $30.00 to $25.00 and set a "buy" rating for the company in a research report on Friday, May 20th. Barclays dropped their price target on shares of Coherus BioSciences from $20.00 to $15.00 in a research report on Monday, May 9th. Finally, UBS Group initiated coverage on shares of Coherus BioSciences in a report on Monday, June 13th. They issued a "neutral" rating and a $7.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Coherus BioSciences presently has an average rating of "Hold" and a consensus price target of $18.40.

Receive CHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter.

CHRS Stock News Headlines

Can This Small-Cap Biotech 5x Revenue by 2026?
Coherus: Will Its Chinese Gambit Fail?
See More Headlines
Receive CHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter.

CHRS Company Calendar

Last Earnings
8/04/2022
Today
8/14/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CHRS
Fax
N/A
Employees
332
Year Founded
2010

Price Target and Rating

Average Stock Price Forecast
$18.40
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+33.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-287,100,000.00
Pretax Margin
-83.47%

Debt

Sales & Book Value

Annual Sales
$326.55 million
Book Value
($0.29) per share

Miscellaneous

Free Float
68,468,000
Market Cap
$1.07 billion
Optionable
Optionable
Beta
1.19

Social Links















CHRS Stock - Frequently Asked Questions

Should I buy or sell Coherus BioSciences stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CHRS shares.
View CHRS analyst ratings
or view top-rated stocks.

What is Coherus BioSciences' stock price forecast for 2022?

4 Wall Street analysts have issued 12 month target prices for Coherus BioSciences' stock. Their CHRS share price forecasts range from $7.00 to $30.00. On average, they anticipate the company's share price to reach $18.40 in the next year. This suggests a possible upside of 33.7% from the stock's current price.
View analysts price targets for CHRS
or view top-rated stocks among Wall Street analysts.

How have CHRS shares performed in 2022?

Coherus BioSciences' stock was trading at $15.96 at the beginning of the year. Since then, CHRS shares have decreased by 13.8% and is now trading at $13.76.
View the best growth stocks for 2022 here
.

When is Coherus BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our CHRS earnings forecast
.

How were Coherus BioSciences' earnings last quarter?

Coherus BioSciences, Inc. (NASDAQ:CHRS) released its earnings results on Thursday, August, 4th. The biotechnology company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.17. Coherus BioSciences had a negative trailing twelve-month return on equity of 422.10% and a negative net margin of 83.47%. During the same period last year, the firm earned ($0.40) earnings per share.

What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO?

21 employees have rated Coherus BioSciences Chief Executive Officer Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among the company's employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Coherus BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

What is Coherus BioSciences' stock symbol?

Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."

Who are Coherus BioSciences' major shareholders?

Coherus BioSciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (1.39%), Northern Trust Corp (0.96%), Scout Investments Inc. (0.89%), Deutsche Bank AG (0.88%), Platinum Investment Management Ltd. (0.77%) and Principal Financial Group Inc. (0.61%). Insiders that own company stock include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, Mcdavid Stilwell, Vincent R Anicetti and Vladimir Vexler.
View institutional ownership trends
.

How do I buy shares of Coherus BioSciences?

Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Coherus BioSciences' stock price today?

One share of CHRS stock can currently be purchased for approximately $13.76.

How much money does Coherus BioSciences make?

Coherus BioSciences (NASDAQ:CHRS) has a market capitalization of $1.07 billion and generates $326.55 million in revenue each year. The biotechnology company earns $-287,100,000.00 in net income (profit) each year or ($2.98) on an earnings per share basis.

How many employees does Coherus BioSciences have?

The company employs 332 workers across the globe.

Does Coherus BioSciences have any subsidiaries?

The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc..
Read More

When was Coherus BioSciences founded?

Coherus BioSciences was founded in 2010.

How can I contact Coherus BioSciences?

Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The official website for the company is www.coherus.com. The biotechnology company can be reached via phone at (650) 649-3530 or via email at darrington@coherus.com.

This page (NASDAQ:CHRS) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.